

Chao-Hua Chiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1629498/publications.pdf>

Version: 2024-02-01

59
papers

2,128
citations

331538

21
h-index

243529

44
g-index

59
all docs

59
docs citations

59
times ranked

2466
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	5.1	418
2	Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1² trials. <i>Lancet Oncology</i> , The, 2020, 21, 261-270.	5.1	303
3	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 793-799.	0.5	199
4	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. <i>Lung Cancer</i> , 2005, 47, 129-138.	0.9	132
5	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1907-1918.	0.5	85
6	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 637-648.	0.5	83
7	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1253-1263.	0.8	74
8	Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1302-1312.	3.2	74
9	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	0.5	70
10	Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: preliminary report. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 125, 1300-1305.	0.4	46
11	Histological Subtypes of Lung Adenocarcinoma Have Differential 18F-Fluorodeoxyglucose Uptakes on the Positron Emission Tomography/Computed Tomography Scan. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1697-1703.	0.5	46
12	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA8507-LBA8507.	0.8	46
13	Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. <i>Lung Cancer</i> , 2007, 57, 213-221.	0.9	37
14	Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. <i>Oncotarget</i> , 2016, 7, 46628-46635.	0.8	36
15	Lung Cancer in Republic of China. <i>Journal of Thoracic Oncology</i> , 2021, 16, 519-527.	0.5	34
16	Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3605-3605.	0.8	33
17	Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer. <i>Journal of the Chinese Medical Association</i> , 2016, 79, 248-255.	0.6	32
18	Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9008-9008.	0.8	30

#	ARTICLE	IF	CITATIONS
19	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
20	Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer. <i>PLoS ONE</i> , 2020, 15, e0236503.	1.1	25
21	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	1.3	24
22	Latent TB infection in newly diagnosed lung cancer patients – A multicenter prospective observational study. <i>Lung Cancer</i> , 2014, 85, 472-478.	0.9	23
23	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9000-9000.	0.8	23
24	Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 661-665.	1.1	22
25	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	3.2	19
26	Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY. <i>Cancer Science</i> , 2020, 111, 4510-4525.	1.7	17
27	MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. <i>Oncotarget</i> , 2015, 6, 8407-8417.	0.8	17
28	Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays. <i>Journal of Thoracic Oncology</i> , 2014, 9, 91-96.	0.5	14
29	Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 16122.	1.6	13
30	Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI. <i>Targeted Oncology</i> , 2020, 15, 503-512.	1.7	12
31	Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis. <i>Targeted Oncology</i> , 2021, 16, 207-214.	1.7	9
32	The predictive value of the interferon- γ release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 115, 64-70.	0.9	8
33	Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1817-1826.	0.8	8
34	Erlotinib in patients with advanced lung squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 203-208.	1.1	7
35	Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups. <i>Spinal Cord</i> , 2020, 58, 194-202.	0.9	7
36	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100156.	0.6	6
38	Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. <i>Oncotarget</i> , 2018, 9, 5435-5444.	0.8	6
39	Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis. <i>Frontiers in Bioscience</i> , 2021, 26, 1679-1688.	0.8	6
40	Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. <i>PLoS ONE</i> , 2022, 17, e0267362.	1.1	6
41	Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9015-9015.	0.8	6
42	Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1439-1441.	0.8	4
43	Early circulating tumor (ct) DNA dynamics and efficacy of lorlatinib: Analysis from the CROWN study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9011-9011.	0.8	4
44	Pathological complete response after afatinib treatment of stage IV oligometastatic adenocarcinoma of the lung: the role of pulmonary surgery. <i>Surgical Case Reports</i> , 2019, 5, 178.	0.2	4
45	Economic Analysis of Exclusionary EGFR Test Versus Up-Front NGS for Lung Adenocarcinoma in High EGFR Mutation Prevalence Areas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 774-782.e4.	2.3	4
46	Efficacy/safety of entrectinib in patients (pts) with <i>ROS1</i>-positive<i> (ROS1</i>+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA9023-LBA9023.	0.8	4
47	Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. <i>Lung Cancer</i> , 2019, 138, 52-57.	0.9	3
48	Pneumatosis intestinalis induced by targeted therapy. <i>Postgraduate Medical Journal</i> , 2022, 98, 10-10.	0.9	2
49	Epidermal growth factor receptor mutations in non-“small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction”-based assays. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 345-349.	0.6	2
50	A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9631-TPS9631.	0.8	2
51	Cytology-“Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non-“Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 810124.	1.3	2
52	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2
53	Sequence for Surgical Resection of Primary Lung Tumor for Oligometastatic Non-small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1333-1340.	0.7	1
54	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1214).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4101-4101.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Impending myxedema coma as the initial presentation of lung cancer. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 488-489.	0.8	0
56	Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?. <i>Surgical Case Reports</i> , 2021, 7, 138.	0.2	0
57	Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8043-8043.	0.8	0
58	The impact of different brain imaging strategies for initial staging and post-treatment surveillance in patients with EGFR-mutant lung adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21145-e21145.	0.8	0
59	Evaluating PD-L1 status and its correlation with clinical features in surgically resected lung adenocarcinoma patients: Comparison of tissue microarrays and whole tissue section.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8548-8548.	0.8	0